替吉奥联合吉西他滨治疗转移性胰腺癌的疗效观察  

Clinical research of S-1 combined gemcitabine treatment in patients with metastatic pancreatic cancer

作　　者：刘为军[1] 王昆华[1] 郭世奎[1] 雷毅[1] 徐玉[1] 陈贤玉[1] 孙若飞[1] 

机构地区：[1]昆明医科大学附属云南省第一人民医院,云南省肠外肠内营养学研究中心,昆明650032

出　　处：《山东医药》2013年第5期39-40,共2页Shandong Medical Journal

基　　金：云南省科技计划项目(2010CD196)

摘　　要：目的探讨替吉奥(S-1)联合吉西他滨(GEM)治疗转移性胰腺癌的疗效及安全性。方法选择41例未接受化、放疗的转移性胰腺癌患者,随机分为观察组21例、对照组20例。2组均采用抗肿瘤综合治疗,在此基础上,对照组给予GEM 1 000 mg/m2、第1、8、15天静滴;观察组给予GEM 1 000 mg/m2、第1、15天静滴,同时给予S-1胶囊80 mg/(m2.d)分早晚2次口服,第1～14天。4周为1个疗程。2个疗程后,观察2组疗效及毒副反应情况。结果观察组有效率为28.6%,疾病控制率为71.4%;对照组分别为20.0%、45.0%。2组疾病控制率比较差异有统计学意义(P<0.05)。两组主要毒副反应均以消化道和血液学毒性为主,对照组毒副反应重于观察组(P<0.05)。结论 S-1联合GEM治疗转移性胰腺癌安全、有效。Objective To study about efficacy and safety of combining S-1 with gemcitabine to treat patients with metastatic pancreatic cancer. Methods 41 patients with measurable lesions and not previously chemotherapy and radiothera- py metastatic pancreatic cancer patients were randomly divided into two groups. The observation group （GS group） 21 patients with gemcitabine 1 000 mg/m^2, the 1st and the 15th day were intravenously injected respectively, S-1 capsule 80 mg/（ m^2 · d）, bid, from d1-14, 4 weeks for a period of treatment. Control group （GEM group） and patients were treated with gemcitabine 1 000 mg/m^2, day 1,8 days and 15 days intravenous drug, 4 weeks for a period of treatment. Results GS group of 21 cases, the total effective rate was 28.6%, disease control rates was 71.4%. GEM group of 20 cases, the total effective rate was 20.0%, disease control rates was 45.0%. The difference of disease control rates between the two groups had statistical significance （ P 〈 0.05 ）. Major adverse reaction of two groups were mild gastrointestinal reaction and hematology toxicity. The difference of major adverse reaclion between the two groups had statistical significance （P 〈 0.05）. Conclusions S-1 combined with gemcitabine in treating patients with metastatic pancreatic cancer has better efficacy and tolerance.

关 键 词：胰腺肿瘤 替吉奥 吉西他滨 抗肿瘤联合化疗方案 

分 类 号：R735.9[医药卫生—肿瘤]